Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2021-11-03 00:00:00 ET · period of report 2021-11-01 · accession 0001179110-21-009815 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-03 | 2021-11-01 | CLDX | Heath-Chiozzi Margo | SVP of Regulatory Affairs | M - OptEx | $2.78 | +600 | 11.8K | +5% | +$1,668 |
| D | 2021-11-03 | 2021-11-01 | CLDX | Heath-Chiozzi Margo | SVP of Regulatory Affairs | S - Sale+OE | $41.71 | -600 | 11.2K | -5% | -$25.0K |
| D | 2021-11-03 | 2021-11-01 | CLDX | Heath-Chiozzi Margo | SVP of Regulatory Affairs | M - OptEx | $0.00 | -600 | 42.4K | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-01 | M | A | 600 | $2.78 | 11,847 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-01 | S | D | 600 | $41.71 | 11,247 | D | — | — | (F1) The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021. |
| 3 | Derivative | Incentive Stock Option (Right to Buy) | 2021-11-01 | M | D | 600 | $0.00 | 42,400 | D | $2.78 · — to 2029-06-19 | 600 Common Stock | (F2) 25 % vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |